Repligen (NASDAQ:RGEN) Given New $200.00 Price Target at JPMorgan Chase & Co.
Repligen (NASDAQ:RGEN – Get Free Report) had its target price boosted by equities research analysts at JPMorgan Chase & Co. from $190.00 to $200.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a […]
Repligen (NASDAQ:RGEN – Get Free Report) had its target price boosted by equities research analysts at JPMorgan Chase & Co. from $190.00 to $200.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a […]
